Moderna shares climbed 4.9% in the previous session, lifted by a higher price target and anticipation of key study data. But the day’s gain tells a smaller story than the forces now converging on the stock: a completed index inclusion that mechanically draws fresh demand, a five-year research pact with Australia’s national science agency, and two autumn dates that will test whether expectations can survive contact with actual results.
Two Analysts, Two Directions
Goldman Sachs analyst Salveen Richter raised her price target on Moderna from $120 to $137, according to media reports, while keeping her rating at Neutral. The distinction matters. A higher target signals improved valuation relative to the bank’s prior view, but it is not a buy recommendation — and anyone reading only the headline number misses that caveat.
Citi’s Geoff Meacham moved the other way, reiterating a Sell rating with an $80 target. The two calls frame the tension running through the stock: the market is rewarding expectations, while analysts draw sharply different conclusions from the same set of facts. That divergence is more informative than the simple fact that one target went up.
The Index Seat Is Already Filled
Moderna’s addition to the Nasdaq-100 took effect before the opening bell on October 9, replacing Warner Bros. Discovery. Nasdaq had announced the change on October 1. Media reports credit the inclusion with acting as a demand impulse for the shares.
This is a structural force, not a clinical one. Index membership can generate buying from funds that track the benchmark, and at Moderna that mechanical demand has arrived at the same moment as enthusiasm for the company’s cancer vaccine program. The two should be kept separate in any assessment: the index seat is a done deal, while the vaccine hopes rest on data still to come. Extra demand for a stock is not the same thing as extra proof from a trial — a distinction that gets lost when the price chart is rising.
A Five-Year Research Bet on Hendra
Beyond the trading floor, Moderna has expanded its research footprint. CSIRO, Australia’s national science agency, said on October 10 that it had entered a five-year partnership with the company. The first joint project will explore potential human vaccines against the Hendra virus, with the broader aim of developing countermeasures against biological threats.
Should investors sell immediately? Or is it worth buying Moderna?
For investors, this collaboration sits alongside — not in place of — the clinical and financial milestones on the calendar. It is a research undertaking, not evidence of a market-ready product. It also represents a different track from the cancer vaccine work: the Hendra program is an additional development direction, while the melanoma candidate is already being studied in a Phase 3 trial. The two should be weighed separately. The partnership describes a long-horizon research task; the upcoming clinical readouts can offer a more concrete look at a program that is further along.
Two Dates That Carry the Real Weight
On October 24, Moderna and Merck are due to present detailed Phase 3 results for their experimental personalized cancer vaccine against melanoma at the ESMO congress. That is the next hard clinical checkpoint.
Then, on November 6, Moderna has said it will release third-quarter 2026 financial results alongside a company report. The two events serve as different kinds of tests. The study data speak to clinical development; the earnings report turns the spotlight on the business figures. Neither can be substituted by an index membership.
Moderna is currently running two market narratives that can reinforce each other but should not be confused. One is about attention and demand. The other is about clinical and economic outcomes. Yesterday’s advance shows that expectations are finding support. Whether that support holds is a question for the announced releases — not for the price move itself.
Ad
Moderna Stock: Buy or Sell?! New Moderna Analysis from October 16 delivers the answer:
The latest Moderna figures speak for themselves: Urgent action needed for Moderna investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 16.
Moderna: Buy or sell? Read more here...
